Erectile Dysfunction
This page hosts the operative decision support for erectile dysfunction (ED) — the stepwise framework from lifestyle modification through PDE5 inhibitors, intracavernosal injection, vacuum erection device, intraurethral alprostadil, regenerative therapy, and penile-prosthesis implantation, including infection salvage. For pathophysiology, evaluation, and natural history, see Erectile Dysfunction in Clinical Conditions. For implant-specific operative deep-dives, see the Penile Implants subsection.
Decision Framework
ED management follows a stepwise, patient-centered algorithm endorsed by the AUA 2018 Erectile Dysfunction Guideline and the EAU 2025 Male Sexual & Reproductive Health Update, progressing from least to most invasive with treatment selection guided by severity, etiology, comorbidities, and patient/partner preference.[1][2] The EAU 2025 update emphasizes personalized treatment — patients should be fully counseled on every available modality and choose based on invasiveness, tolerability, effectiveness, and personal expectations.[2] Combination therapy is superior to monotherapy across multiple PDE5i-based combinations and should be optimized before advancing to prosthesis.[4] For prosthesis infection, immediate Mulcahy salvage preserves penile length (mean 0.6 cm loss vs 3.7 cm with delayed reimplantation).[14][15]
Treatment Selection by Clinical Scenario
| Clinical Scenario | First-Line | Alternative(s) | Avoid |
|---|---|---|---|
| Newly diagnosed ED, no contraindications | Lifestyle modification + PDE5 inhibitor, titrated to maximum dose with ≥6 properly executed attempts | Daily tadalafil 2.5–5 mg if concurrent BPH/LUTS or preference for spontaneity | Skipping cardiovascular risk assessment; declaring failure before maximum-dose trial |
| Confirmed hypogonadism (morning total T <300 ng/dL) + ED | PDE5i + testosterone replacement | PDE5i monotherapy (often suboptimal in hypogonadal men) | Testosterone monotherapy without PDE5i |
| PDE5i non-responder after ≥6 max-dose attempts | Combination therapy: switch agent → PDE5i + VED → daily tadalafil → PDE5i + intraurethral alprostadil | Intracavernosal injection (ICI) | Premature progression to prosthesis without optimization |
| PDE5i failure / intolerance, prefers pharmacotherapy | ICI (alprostadil → bimix → trimix), in-office training and home dose titration | MUSE (intraurethral alprostadil) | Self-titration without supervised first dose (priapism risk) |
| Prefers non-pharmacologic option | Vacuum erection device | MUSE | Restrictive ring >30 minutes (ischemia risk) |
| Concurrent nitrate use (any formulation) | VED, ICI (alprostadil monotherapy) | MUSE | All PDE5 inhibitors (absolute contraindication) |
| Post-radical prostatectomy ED (early, <12–24 months) | Penile rehabilitation: PDE5i ± VED ± ICI | Daily tadalafil | "Watch and wait" without rehabilitation |
| Mild–moderate vasculogenic ED, partial PDE5i response, prefers regenerative adjunct | Li-ESWT + PDE5i | PRP (investigational) | Stem-cell therapy (investigational; outside guideline) |
| Refractory to optimized conservative + medical therapy, or patient preference | 3-piece IPP (AMS 700 series or Coloplast Titan) | 2-piece IPP (prior pelvic surgery, reservoir contraindication); malleable (limited dexterity, neophallus, salvage, cost-constrained) | Continued failed pharmacotherapy without device counseling |
| Peyronie's disease + ED unresponsive to medical therapy | IPP with adjunctive straightening (Wilson manual modeling → tunical plication → plaque incision/grafting as needed) | (See Peyronie's algorithm) | IPP alone without addressing curvature |
| Severe corporal fibrosis (post-priapism, post-explant) | Malleable prosthesis at high-volume center | Staged dilation → 3-piece IPP | Standard 3-piece in densely fibrosed corpora without dilation strategy |
| Acute prosthesis infection | Immediate Mulcahy salvage (washout + same-session reimplant — IPP or malleable) | Extracapsular reimplantation (mature capsule) | Delayed reimplantation (mean 3.7 cm corporal length loss vs 0.6 cm with immediate salvage) |
| Young man with traumatic arterial injury (no atherosclerosis) | Penile arterial revascularization at high-volume center (IEA → dorsal penile artery, Michal II) | ICI / PDE5i bridge during workup | Revascularization for atherosclerotic ED (poor outcomes) |
Stepwise Treatment Ladder
| Step | Tier | Expected Efficacy | When to Advance |
|---|---|---|---|
| 0 | Lifestyle modification + risk-factor optimization (weight loss, exercise, smoking cessation, medication review, treat hypogonadism) | IIEF improvement of 3–5 points with structured programs[1] | Insufficient response, or patient desires faster improvement |
| 1 | PDE5 inhibitor monotherapy at maximum tolerated dose | 60–70% successful intercourse[3] | Failure after dose titration + counseling |
| 1B | Combination therapy — PDE5i + testosterone (if hypogonadal), PDE5i + VED, agent switch, daily tadalafil | Superior to monotherapy across IIEF in JAMA Netw Open meta of 59 RCTs[4] | Failure of optimized combination |
| 2A | Intracavernosal injection (alprostadil, bimix, or trimix) | Up to 70% with alprostadil; up to 90% with trimix[3][8] | Failure, intolerance, >50% dropout, or patient preference for definitive solution |
| 2B | Intraurethral alprostadil (MUSE) or vacuum erection device | MUSE 43–69%; VED 60–80%[3] | Insufficient response or dissatisfaction |
| 2.5 | Regenerative therapy — Li-ESWT (best evidence), PRP (emerging) | Li-ESWT mean IIEF +2.0 (95% CI 0.99–3.00, p < 0.001) in meta of 14 studies[6]; investigational, not yet guideline-recommended as standalone[5][7] | Insufficient response → Step 3 |
| 3 | Penile prosthesis implantation (3-piece IPP preferred) | 70–90% patient and partner satisfaction[9][10] | Definitive endpoint; irreversible |
IPP Device-Selection Sub-Comparison
| Feature | 3-Piece IPP | 2-Piece IPP | Malleable (Semi-Rigid) |
|---|---|---|---|
| Components | Two cylinders + scrotal pump + retropubic (or ectopic) reservoir | Two cylinders + combined pump-reservoir in scrotum | Two bendable rods |
| Naturalness | Most natural erection / flaccidity — gold standard | Intermediate rigidity; limited fluid volume | Always semi-rigid — concealment difficult |
| Mechanical survival | >90% at 5 years with modern devices[10][11] | >90% at 5 years | Highest — no hydraulic components |
| Surgical complexity | Most complex (reservoir placement) | Avoids retropubic reservoir | Simplest |
| Cost | Highest | Intermediate | Lowest |
| Ideal candidate | Standard candidate with adequate dexterity, no reservoir contraindication | Prior pelvic / abdominal surgery making reservoir placement risky | Limited dexterity; neophallus; cost constraints; salvage after infection |
Prosthesis Infection Salvage — Length-Preservation Hierarchy
| Strategy | Technique | Infection-Free Rate | Length Impact |
|---|---|---|---|
| Immediate IPP salvage (Mulcahy) | 7-solution antiseptic / antibiotic washout + same-session IPP reimplantation[14][12] | 82% long-term | Mean 0.6 cm loss[15] |
| Immediate malleable salvage | Mulcahy washout + malleable prosthesis; later elective conversion to IPP at ~6.7 mo in ~31%[13] | 93% single-center; 70.5% in 2026 VA national n = 76 (45.5% reinfection in diabetics)[16] | Preserves length |
| Extracapsular salvage | Explant infected device, wash capsule, reimplant in extracapsular sinusoidal space[17] | 94.4% (n = 18) | Bypasses contaminated capsule |
| Delayed reimplantation | Explant, wait 3–6 months, reimplant | Standard | Mean 3.7 cm corporeal length loss, irreversible[15] |
The Lopategui 2018 finding is the operational anchor: delayed reimplantation costs ~3.7 cm of corporeal length, regardless of time-to-reimplant interval, while immediate salvage costs ~0.6 cm. Salvage should be offered at presentation whenever the patient is medically suitable.[15]
Treatment Database
| Treatment | Tier | Invasiveness |
|---|---|---|
| Lifestyle Modification | Lifestyle / Behavioral | Non-invasive |
| Psychosexual Therapy | Lifestyle / Behavioral | Non-invasive |
| PDE5 Inhibitors | Oral Pharmacotherapy | Non-invasive |
| Testosterone Replacement Therapy | Oral Pharmacotherapy | Non-invasive |
| Vacuum Erection Device (VED) | Mechanical | Non-invasive |
| Intraurethral Alprostadil (MUSE) | Intraurethral | Minimally Invasive |
| Intracavernosal Injection | Injectable | Minimally Invasive |
| Low-Intensity Shockwave Therapy (Li-ESWT) | Regenerative / Emerging | Non-invasive |
| Platelet-Rich Plasma (PRP) | Regenerative / Emerging | Minimally Invasive |
| Stem Cell Therapy | Regenerative / Emerging | Minimally Invasive |
| Penile Implant | Surgical Prosthesis | Surgical Implant |
| Penile Arterial Revascularization | Vascular Surgery | Surgical Open |
| Venous Ligation Surgery (± Embolization) | Vascular Surgery | Surgical Open |
See Also
- Erectile Dysfunction (Clinical Conditions) — pathophysiology, evaluation, full clinical workup
- Penile Implants subsection
- Peyronie's Disease — operative decision support
- Pharmacology — Sexual Medicine & Andrology
References
1. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004
2. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. Eur Urol. 2025;88(1):76–102. doi:10.1016/j.eururo.2025.04.010
3. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–488. doi:10.1016/j.jsxm.2016.01.016
4. Mykoniatis I, Pyrgidis N, Sokolakis I, et al. Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(2):e2036337. doi:10.1001/jamanetworkopen.2020.36337
5. Ergun O, Kim K, Kim MH, et al. Low-intensity shockwave therapy for erectile dysfunction. Cochrane Database Syst Rev. 2025;7:CD013166. doi:10.1002/14651858.CD013166.pub3
6. Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71(2):223–233. doi:10.1016/j.eururo.2016.05.050
7. Capogrosso P, Albersen M, Burnett AL, et al. Erectile dysfunction: update on clinical management. Eur Urol. 2025:S0302-2838(25)00282-9. doi:10.1016/j.eururo.2025.05.004
8. Lima AS, Villela BC, Pustilnik HN, et al. Comparison of adverse effects of combined and isolated substances in intracavernosal injection: a systematic review and meta-analysis. J Sex Med. 2025:qdaf172. doi:10.1093/jsxmed/qdaf172
9. Goodstein T, Jenkins LC. A narrative review on malleable and inflatable penile implants: choosing the right implant for the right patient. Int J Impot Res. 2023;35(7):623–628. doi:10.1038/s41443-023-00765-7
10. Levine LA, Becher EF, Bella AJ, et al. Penile prosthesis surgery: current recommendations from the International Consultation on Sexual Medicine. J Sex Med. 2016;13(4):489–518. doi:10.1016/j.jsxm.2016.01.017
11. Ancha N, Eldin M, Woodle T, et al. Current devices, outcomes, and pain management considerations in penile implant surgery: an updated review of the literature. Asian J Androl. 2024;26(4):335–343. doi:10.4103/aja202386
12. Mahdi M, Campos LR, Yafi FA. Immediate salvage procedure for infected penile prostheses: a review of the advances in surgical technique and antimicrobial strategies. Int J Impot Res. 2025. doi:10.1038/s41443-025-01133-3
13. Gross MS, Phillips EA, Balen A, et al. The malleable implant salvage technique: infection outcomes after Mulcahy salvage procedure and replacement of infected inflatable penile prosthesis with malleable prosthesis. J Urol. 2016;195(3):694–697. doi:10.1016/j.juro.2015.08.091
14. Swanton AR, Gross MS, Munarriz RM, Mulcahy JJ. Penile prosthesis salvage: a historical look at the Mulcahy technique and a review of the latest literature. Int J Impot Res. 2023;35(2):90–94. doi:10.1038/s41443-021-00515-7
15. Lopategui DM, Balise RR, Bouzoubaa LA, Wilson SK, Kava BR. The impact of immediate salvage surgery on corporeal length preservation in patients presenting with penile implant infections. J Urol. 2018;200(1):171–177. doi:10.1016/j.juro.2018.01.082
16. Angulo-Llanos L, Sandler MD, Howell NB, Williams A, Masterson III TA. Outcomes of salvage procedures with malleable implants for penile prosthesis infections in the Veterans Affairs national medical system: a real-world, multi-surgeon retrospective analysis over a decade. J Sex Med. 2026;23(3):qdag042. doi:10.1093/jsxmed/qdag042
17. Shaeer O, Shaeer K, Soliman AbdelRahman IF. Salvage and extracapsular implantation for penile prosthesis infection or extrusion. J Sex Med. 2019;16(5):755–759. doi:10.1016/j.jsxm.2019.02.005